Allrock Bio has raised $50 million in financing to support the clinical development of pulmonary hypertension (PH) treatment ROC-101. The company said it will use the funds to launch a Phase 2a clinical trial to test ROC-101 in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). Allrock said the […] The post Allrock gets financing to start trial of PH treatment this year appeared first on Pulmonary Hypertension News.
